Update on Ambrose Healthcare shareholding
21 October 2026
ValiRx PLC
("ValiRx" or the "Company")
Update on Ambrose Healthcare shareholding
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, notes the movement in the Company's share price on 20 October 2026 following the announcement by Ambrose Healthcare Ltd ("Ambrose"), a private UK specialist pharmaceutical company, regarding its acquisition of AM-Pharma for up to €161 million.
On 20 June 2025, ValiRx announced that its 54.14% owned subsidiary, ValiSeek Ltd ("ValiSeek"), a joint venture alongside Tangent Reprofiling, had entered into an intellectual property licence agreement with Ambrose in relation to VAL401. Under the agreement, ValiSeek received 576,000 ordinary shares in Ambrose and is entitled to clinical and commercial milestone payments of up to £16 million, together with royalties. In addition, ValiSeek received 75,000 ordinary shares in Ambrose in connection with the original option agreement. These shareholdings represents approximately 5.55% of Ambrose's issued share capital.
Mark Eccleston, CEO of ValiRx commented:
"As the third largest shareholder in Ambrose, we're delighted to see the acquisition of this additional clinical stage asset with established positive safety in almost 700 patients. The asset, which has had over $250M invested into sepsis-associated kidney injury including a Phase 3 trial that ultimately gave disappointing results, now has demonstrated dose-dependent effect on disease biomarkers in a Phase 1b study in adult HPP patients and has received Orphan Drug Designation for HPP from both the FDA and the EMA, with an agreed development plan built around a single pivotal study giving the programme a new lease of life with an established early clinical package. The acquisition also gives Ambrose an EU regulatory, quality and scientific infrastructure as a strong base for their pipeline which includes ValiSeek's VAL401 asset. Given the previous big pharma interest in the asset and accelerated clinical pathway via the orphan disease route we think this could be a fast tracked route to a significant value inflection for Ambrose and thus ValiRx through its shareholding."
The Directors of the Company take responsibility for this announcement.
*** ENDS ***
Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: https://valirx.com/s/cc8ef3
For more information, please contact:
|
Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub |
https://valirx.com/link/P7NqJr
|
|
ValiRx plc Dr Mark Eccleston, CEO |
Tel: +44 115 784 0026 Mark.Eccleston@valirx.com |
|
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti |
Tel: +44 (0) 20 7213 0880 |
|
Shard Capital Partners LLP (Sole Broker) Damon Heath |
Tel: +44 (0) 20 4530 6926
|
|
V Formation (Public Relations) Jocelyn Braithwaite |
+44 (0) 115 646 5491 www.vformation.co.uk jocelyn@vformation.co.uk |
Subscribe to our news alert service: https://valirx.com/s/f298d1
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE